Fosun Pharma (02196) announced interim results: 截至2026年6月30日止六個月之中期業績公告, net profit attributable to owners RMB17.2bn Title: 截至2026年6月30日止六個月之中期業績公告 Revenue: RMB203.8bn Net profit: RMB21.5bn Profit attributable to owners: RMB17.2bn
